New drug combo shows promise for rare pompe disease
NCT ID NCT02675465
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tested two experimental drugs, ATB200 and AT2221, given together to adults with Pompe disease. The goal was to see if the combination is safe and how the body handles it. 29 participants received the drugs through an IV and a pill. The study found that the treatment was generally safe, with some side effects, and helped improve walking distance and lung function in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMPE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center Chester County Hospital
West Chester, Pennsylvania, 19380, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory University Division of Medical Genetics
Decatur, Georgia, 30033, United States
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Friedrich-Baur-Institure, Dep of Neurology - University Munich
Munich, 80336, Germany
-
Great Falls Clinic, LLP
Great Falls, Montana, 59405, United States
-
Infusion Associates
Grand Rapids, Michigan, 49525, United States
-
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia, 22030, United States
-
Neuromuscular Research Centre
Phoenix, Arizona, 85028, United States
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Rutgers New Jersey Medical School
Newark, New Jersey, 08103, United States
-
Salford Royal NHS Foundation Trust
Salford, M6 8HD, United Kingdom
-
School of Medicine, University of Auckland
Auckland, 01051, New Zealand
-
University Children's Hospital Department of Neuropediatrics and Inborn Metabolic Disorders, St. Josefs-Hospital
Bochum, 44791, Germany
-
University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Medical Center
Birmingham, B15 2TH, United Kingdom
-
University of California Irvine
Orange, California, 92868, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
Womens & Childrens Hospital, Adelaide
North Adelaide, South Australia, 05006, Australia
Conditions
Explore the condition pages connected to this study.